Oppenheimer raised the firm’s price target on Ensign Group (ENSG) to $170 from $168 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company raised FY2025 EPS guidance to $6.34-$6.46 vs. $6.22-$6.38 based on revenues of $4.99-$5.02B vs. $4.89-$4.94B. Overall, with healthcare companies generally struggling, Ensign is building on its strong consistent track-record, with another impressive beat and raise, says Oppenheimer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSG:
- Ensign Group raises FY25 adjusted EPS view to $6.34-$6.46 from $6.22-$6.38
- Ensign Group reports Q2 adjusted EPS $1.59, consensus $1.55
- Is ENSG a Buy, Before Earnings?
- Ensign Group acquires Timber Spring Transitional Care in Idaho
- Ensign subsidiary acquires Duncanville Healthcare and Rehabilitation Center